Incyte INCY
Incyte FY 2024: revenue $4.2B, up 15%; diluted EPS $0.15
- Form
- 10-K
- Filed
- Period
- Importance
- Notable
- Accession
- 0001628280-25-004633
- Document
- 10-K
Key figures from this report
These are the numbers Incyte reported for the year ended Dec 31, 2024, as tagged in the filing’s XBRL data, each against the year before. A plain-English reading of this report is not written yet.
- Revenue$4.2B+15% from $3.7B in FY 202310-K income statement, on EDGAR
- Net income$32.6M−95% from $597.6M in FY 202310-K income statement, on EDGAR
- Diluted EPS$0.15−94% from $2.65 in FY 202310-K income statement, on EDGAR
- Cash and cash equivalents$1.7B−47% from $3.2B in FY 202310-K balance sheet, on EDGAR
- Cash from operations$335.3M−32% from $496.5M in FY 202310-K cash flow statement, on EDGAR
Similar companies
Companies of similar size in SIC 8731 and related industry codes: the same peer list as the financial tables.
- Charles River Laboratories International CRL public float $7.3B, Jun 28, 2025
- Medpace Holdings MEDP public float $7.0B, Jun 30, 2025
- Iqvia Holdings IQV public float $26.5B, Jun 30, 2025
- UL Solutions ULS public float $4.5B, Jun 30, 2025
